Publication Name	World Journal of Experimental Medicine
Manuscript ID	114526
Country	Egypt

Category	Oncology
Manuscript Type	Letter to the Editor
Article Title	Leukoplakia of oral cavity and urinary bladder are premalignant to squamous carcinoma
Manuscript Source	Invited Manuscript
All Author List	Mohamed Wishahi
Funding Agency and Grant Number
Corresponding Author	Mohamed Wishahi, MD, PhD, Professor, Department of Urology, Theodor Bilharz Research Institute, Embaba, Giza, Cairo 12411, Egypt. moh.weshahy@gmail.com
Key Words	Leukoplakia; Squamous cell carcinoma; Programmed cell death-ligand 1; Immune checkpoint inhibitors; Oral cancer; Bladder cancer
Core Tip	Oral leukoplakia and urinary bladder leukoplakia are premalignant lesions that progress to squamous cell carcinoma (SCC), both lesions and their corresponding SCC express programmed cell death-ligand 1 (PD-L1) indicating response to PD-L1 inhibitors. A recent approach with consideration of recent finding of expression of PD-L1, genetic analysis, microenvironment landscape, recruited clinical trials, and animal model studies would advocate possible treatment of oral leukoplakia with PD-L1 inhibitors aiming at cure and prevent progression to SCC.
Citation	Wishahi M. Leukoplakia of oral cavity and urinary bladder are premalignant to squamous carcinoma. World J Exp Med 2025; in press

Received	2025-09-22 02:01
Peer-Review Started	2025-09-22 02:01
First Decision by Editorial Office Director	2025-10-29 09:20
Return for Revision	2025-10-29 09:20
Revised	2025-11-06 17:24
Publication Fee Transferred
Second Decision by Editor	2025-12-29 02:32
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2025-12-29 06:56
Articles in Press	2025-12-29 06:56
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	2220-315x (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com